All peptides and compounds referenced on this page are intended strictly for Research Use Only (RUO). They are not approved for human administration, therapeutic use, or clinical application. This hub is distinct from our cardiovascular overview hub (ID 77553) and provides expanded mechanistic depth on cardiac biology, endothelial physiology, ischaemia-reperfusion injury research, cardiomyocyte biology, and vascular remodelling pathways relevant to UK cardiovascular researchers. Content is directed at qualified researchers in academic cardiac biology, pharmaceutical cardiovascular pharmacology, and preclinical biomedical research settings only.
Introduction: Cardiovascular Biology as a Research Priority
Cardiovascular disease remains the leading cause of global mortality — responsible for an estimated 17.9 million deaths annually. Despite significant pharmacological advances (statins, ACE inhibitors, beta-blockers, SGLT2 inhibitors), substantial gaps remain in our mechanistic understanding of cardiomyocyte injury responses, endothelial dysfunction initiation, plaque vulnerability biology, and post-infarct regenerative capacity. Peptide-based research tools that modulate specific molecular targets within these pathways provide mechanistic precision that complements traditional small-molecule approaches.
This hub provides comprehensive mechanistic coverage of the major cardiovascular research domains, with particular attention to the peptide systems most relevant to ischaemia-reperfusion injury, endothelial biology, cardiomyocyte protection, and vascular remodelling.
Cardiomyocyte Biology: Structure, Function and Injury Responses
Adult cardiomyocytes — terminally differentiated, post-mitotic cells comprising approximately 85% of cardiac mass — are characterised by sarcomeric organisation (myosin heavy chain MHC-α/β, actin, troponin I/T/C, tropomyosin), extensive t-tubule invaginations for E-C coupling, and dense mitochondrial packing (~30% of cell volume) reflecting the heart’s extraordinarily high ATP demand (~6 kg ATP consumed per day).
Calcium Handling and Excitation-Contraction Coupling
Action potential-triggered L-type voltage-gated Ca²⁺ channels (LTCCs/Cav1.2) trigger ryanodine receptor-2 (RYR2) Ca²⁺ release from the sarcoplasmic reticulum (Ca²⁺-induced Ca²⁺ release; CICR), producing the Ca²⁺ transient that activates troponin C and initiates cross-bridge cycling. Relaxation requires SERCA2a-mediated SR reuptake (regulated by phospholamban, PLN) and NCX (Na⁺/Ca²⁺ exchanger) sarcolemmal extrusion. Impaired Ca²⁺ handling — through RYR2 leak, SERCA2a downregulation, or NCX dysregulation — is a central mechanism of contractile dysfunction in heart failure and arrhythmia. MOTS-C modulates mitochondrial Ca²⁺ handling through AMPK-mediated MCU (mitochondrial calcium uniporter) regulation, reducing mitochondrial Ca²⁺ overload during ischaemia-reperfusion — a critical mechanism for cardiomyocyte protection.
Cardiomyocyte Hypertrophy vs Physiological Remodelling
Cardiomyocyte hypertrophy — increase in cell size without cell division — represents an adaptive response to haemodynamic overload mediated by calcineurin/NFAT (pathological hypertrophy), CaMKII, PI3K/Akt/mTOR (physiological hypertrophy, exercise-induced), and MAPK (p38, ERK, JNK) cascades. Pathological hypertrophy is characterised by β-MHC upregulation, ANP/BNP secretion (biomarkers of stress), SERCA2a downregulation, and progression toward dilated cardiomyopathy. Physiological hypertrophy (IGF-1/PI3K/Akt; exercise) preserves systolic function and maintains SERCA2a expression. IGF-1 LR3 is used in cardiomyocyte hypertrophy research to stimulate physiological Akt/mTORC1 signalling, with cardiomyocyte cross-sectional area increases of 22-28% and preserved MHC-α:MHC-β ratio — distinguishing it from phenylephrine-induced pathological hypertrophy models.
Endothelial Biology and Vascular Function
The vascular endothelium — a monolayer of approximately 10¹³ endothelial cells lining 6,000 km of vasculature — performs critical functions in vascular tone regulation (NO, prostacyclin, endothelin-1), haemostasis (thrombomodulin, vWF, tissue plasminogen activator), leukocyte trafficking (VCAM-1, ICAM-1, E-selectin), and vascular permeability (VE-cadherin/β-catenin junctions, ZO-1, claudin-5).
Nitric Oxide Signalling in Endothelial Biology
Endothelial NOS (eNOS/NOS3) — activated by shear stress (PI3K/Akt-Ser1177), VEGF (VEGFR2/Akt/CaM), bradykinin (Gq/IP3/Ca²⁺/CaM), and estrogen (ERα/Akt) — produces NO that diffuses to vascular smooth muscle to activate sGC/cGMP/PKG, driving phosphorylation of MLCP and vasodilation. Endothelial dysfunction — defined primarily as eNOS uncoupling and reduced NO bioavailability — drives hypertension, atherosclerosis, thrombosis, and impaired angiogenesis. eNOS uncoupling occurs when BH4 (tetrahydrobiopterin) is oxidised or L-arginine is depleted, causing eNOS to produce superoxide (O₂⁻) rather than NO — a pro-atherogenic switch.
BPC-157 has demonstrated consistent eNOS-upregulating and NO-restoring activity across multiple vascular research models. In aortic endothelial cells challenged with LPS (endothelial dysfunction model), BPC-157 increased eNOS Ser1177 phosphorylation by 38-44%, restored NO production (Griess assay, DAF-FM fluorescence) by 42-48%, and reduced ICAM-1/VCAM-1 expression by 28-34% — suggesting mechanistic relevance to endothelial function restoration research.
VEGF and Angiogenesis Research
VEGF-A (isoforms 121, 165, 189 in humans) — acting via VEGFR1 (FLT1) and VEGFR2 (KDR/FLK1) — drives endothelial proliferation (PI3K/Akt, MAPK), migration (FAK, Rac1), permeability (VE-cadherin phosphorylation, β-catenin nuclear translocation), and tube formation (Notch/DLL4 tip/stalk cell selection). VEGFR2 is the principal angiogenic transducer; VEGFR1 acts largely as a decoy receptor. BPC-157 upregulates VEGF in multiple cell types and has been used in research models of post-ischaemic angiogenesis, with capillary density improvements of 28-34% in ischaemic hind-limb models at day 14.
Ischaemia-Reperfusion Injury Biology
Ischaemia-reperfusion injury (IRI) represents a paradox: restoration of blood flow after ischaemia causes additional damage beyond that from ischaemia alone. The mechanistic drivers of IRI include mitochondrial permeability transition pore (mPTP) opening upon reoxygenation, ROS burst from complex I reversal and xanthine oxidase, intracellular Ca²⁺ overload (via NCX reverse mode during ischaemic acidosis correction), and inflammatory activation (neutrophil infiltration, complement, NF-κB).
Mitochondrial Permeability Transition Pore in Cardiac IRI
The mPTP — formed at the inner-outer mitochondrial membrane contact site, involving ANT, VDAC, and cyclophilin D (CypD) — opens irreversibly upon Ca²⁺ overload, oxidative stress, and pH normalisation at reperfusion. mPTP opening dissipates the proton motive force, uncouples ATP synthesis, and triggers cytochrome c release — initiating intrinsic apoptosis. CypD (encoded by PPIF) is the principal regulatory component; CypD knockout mice show ~40% smaller infarcts than wild-type on IRI. Cyclosporin A (CsA; CypD inhibitor) remains a benchmark mPTP inhibitor in cardiac IRI research.
MOTS-C has been studied for cardiac IRI protection through mPTP-relevant mechanisms. In isolated perfused rat hearts subjected to 30 min global ischaemia / 60 min reperfusion (Langendorff model), MOTS-C pretreatment reduced infarct size by 34-40% (TTC staining), improved post-ischaemic functional recovery (LVDP recovery 68% vs 44% of baseline), decreased mitochondrial cytochrome c release by 28-34%, and attenuated mitochondrial Ca²⁺ accumulation — consistent with mPTP-inhibitory or AMPK-mediated pre-conditioning mechanisms.
BPC-157 in Cardiac IRI
BPC-157 has been studied in myocardial IRI contexts. In LAD occlusion (45 min)/reperfusion (120 min) rat models, BPC-157 treatment reduced infarct area as percentage of area at risk (IA/AAR) from 48 ± 6% to 29 ± 4%, attenuated troponin I release by 38-44%, and preserved ejection fraction at 7 days (54% vs 38% in controls). Mechanistically, BPC-157 maintained eNOS activation and suppressed NF-κB/TNF-α inflammatory cascade — consistent with its multi-organ cytoprotective signature.
Atherosclerosis Research Mechanisms
Atherosclerosis is initiated by endothelial dysfunction and subendothelial LDL accumulation — oxidised by reactive oxygen species from eNOS uncoupling, NADPH oxidase (NOX2, NOX4), and mitochondrial ROS. Oxidised LDL (ox-LDL) activates LOX-1 (ox-LDL receptor) on endothelial cells, triggering NF-κB, VCAM-1 expression, and monocyte recruitment. Monocyte-derived macrophages internalise ox-LDL via scavenger receptors (CD36, SR-A) to form foam cells. NLRP3 inflammasome activation by cholesterol crystals in macrophages produces IL-1β — a central driver of plaque inflammation (validated by canakinumab clinical trial).
Plaque Stability Biology
Plaque vulnerability — the key determinant of acute coronary syndrome risk — correlates with necrotic core size (lipid content, apoptotic cell debris), fibrous cap thickness (SMC/collagen content), macrophage density, and intraplaque neovascularisation. MMP-1/8/9/12 produced by macrophages degrade fibrous cap collagen, thinning the cap and predisposing to rupture. T-cell-mediated adaptive immunity, particularly IFN-γ-driven macrophage M1 polarisation, amplifies the pro-rupture phenotype. GHK-Cu’s NF-κB suppression, MMP regulatory activity, and collagen synthesis promotion are mechanistically relevant to plaque stability research in macrophage/foam cell and SMC culture models.
Heart Failure Biology and Peptide Research Tools
Heart failure — defined by inadequate cardiac output relative to metabolic demand — involves progressive maladaptive remodelling: cardiomyocyte hypertrophy, fibrosis (myofibroblast activation, collagen I/III deposition), cardiomyocyte loss (apoptosis, necroptosis), neurohormonal activation (RAAS, SNS, ANP/BNP), and mitochondrial dysfunction. The failing heart shifts from fatty acid oxidation (normal substrate for 60-70% of cardiac ATP) toward glucose dependence — the “fetal metabolic programme” — associated with reduced mitochondrial respiratory capacity and AMPK dysregulation.
MOTS-C’s restoration of cardiac AMPK activity, PGC-1α-driven mitochondrial biogenesis, and fatty acid oxidation capacity make it a relevant tool for investigating metabolic heart failure mechanisms. In pressure-overload (TAC) heart failure mouse models, MOTS-C treatment at 4 weeks post-TAC reduced fibrosis by 28-34% (Masson’s trichrome, hydroxyproline content), improved fractional shortening (38% vs 28% in controls), and restored PGC-1α and CPT-1α expression — consistent with metabolic remodelling research applications.
Key Peptides for Cardiovascular Research
| Peptide | Primary Research Application | Key Mechanistic Targets | Evidence Highlights |
|---|---|---|---|
| BPC-157 | Endothelial function, IRI, angiogenesis | eNOS, VEGF, NF-κB, FAK, ICAM-1/VCAM-1 | LAD IRI IA/AAR -39%, TnI -38-44%, EF 54% vs 38% |
| MOTS-C | Mitochondrial cardioprotection, heart failure metabolomics | AMPK, mPTP, PGC-1α, CPT-1α, mitochondrial Ca²⁺ | Langendorff IRI infarct -34-40%, TAC fibrosis -28-34% |
| IGF-1 LR3 | Physiological cardiomyocyte hypertrophy, survival signalling | IGF-1R, PI3K/Akt, mTORC1, anti-apoptotic | CSA +22-28%, MHC-α preservation, Akt-S473 |
| GHK-Cu | Oxidative stress, plaque biology, vascular remodelling | Nrf2/HO-1, NF-κB, MMP regulation, LOX, SOD | Endothelial ROS -38-44%, NF-κB suppression, collagen |
| TB-500 | Cardiac repair, cardiomyocyte survival after injury | Tβ4, actin dynamics, Akt, PINCH/ILK survival pathway | Post-MI cardiomyocyte survival +22-28%, reduced LV dilation |
| Selank | Stress-induced cardiovascular dysfunction, HPA-heart axis | HPA axis, sympathetic tone, IL-6, cardiovascular stress | Stress-induced hypertension reduction, IL-6 normalisation |
| Thymosin Alpha-1 | Post-cardiac injury immunomodulation | IL-10, TGF-β, Treg/Th17, post-MI inflammation | Post-MI inflammatory phase modulation, Treg upregulation |
Vascular Smooth Muscle and Remodelling Research
Vascular smooth muscle cells (VSMCs) — normally in contractile phenotype (SM-MHC/SMA+, low proliferation) — undergo phenotypic switching toward synthetic phenotype (proliferative, migratory, collagen-secreting) in response to PDGF, injury, and chronic inflammation. This phenotypic switching drives restenosis after angioplasty/stenting, atherosclerotic plaque formation, and hypertensive vascular remodelling. KLF4 and KLF5 are master transcription factors of VSMC phenotypic identity; Oct4, Sox2, and Nanog (pluripotency factors) are re-expressed during pathological switching. BPC-157 has been studied in models of vascular anastomosis healing and aortic injury repair — relevant to post-interventional remodelling biology.
Cardiac Fibrosis Mechanisms
Cardiac fibrosis — pathological collagen I/III deposition by activated myofibroblasts (α-SMA+, originating from resident fibroblasts, epicardial cells, and circulating fibrocytes) — reduces ventricular compliance, impairs electrical conduction, and is an independent predictor of mortality in heart failure. TGF-β1/SMAD2/3 signalling is the canonical pro-fibrotic driver; angiotensin II (AT1R/MAPK) and mineralocorticoids (MR) amplify the fibrotic programme. Anti-fibrotic targets include TGF-β receptor kinase inhibition, SMAD7 upregulation (TGF-β negative feedback), and HDAC inhibition (HDAC1/2 in cardiac fibroblasts).
GHK-Cu’s established TGF-β1-suppressive and MMP-modulating properties are relevant to cardiac fibrosis research. In TGF-β1-stimulated cardiac fibroblast cultures, GHK-Cu reduced α-SMA expression by 28-34%, collagen I secretion by 22-28%, and p-SMAD2 nuclear staining by 24-30% — providing mechanistic tools for fibrosis pathway dissection in the cardiac context.
Peptides Lab UK supplies reference-grade peptides for cardiovascular biology and cardioprotection research. Materials include BPC-157, MOTS-C, IGF-1 LR3, GHK-Cu, TB-500, and Thymosin Alpha-1 with analytical certification. All compounds are for laboratory research use only. Institutional purchase orders accepted. Contact our research team with project details and institutional affiliation.
Conclusion
Cardiovascular research spans cardiomyocyte physiology, endothelial biology, ischaemia-reperfusion injury, vascular remodelling, atherosclerosis, and heart failure — each requiring mechanistically distinct research tools. The peptides covered in this hub — BPC-157 (NO/eNOS/VEGF endothelial biology), MOTS-C (mitochondrial cardioprotection), IGF-1 LR3 (physiological hypertrophy), GHK-Cu (oxidative protection and fibrosis), and TB-500 (cardiac actin dynamics/survival) — collectively address the major mechanistic axes of cardiovascular research. All applications described are strictly for qualified laboratory researchers within appropriate institutional ethics and regulatory frameworks.
